Article in ACS applied bio materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Alan McLeanDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-7226-7076
Wei ZhangDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan 48105, United States.
Alexander CookeDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, Michigan 48109, United States.
Natalie S PotterDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, Michigan 48109, United States.
Raoul KopelmanDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-7770-8272
Yannis M PaulusDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan 48105, United States.ORCID 0000-0002-0615-628X
Funding
VIVARIUM MODULEP30EY007003 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Antonetti · 1987 to 2026
$17.6M
Multimodal Molecular Imaging of Choroidal NeovascularizationR01EY034325 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yannis Mantas Paulus, XUEDING WANG · 2023 to 2026
$2.5M
Development of Nanoneedle Array for Painless and Long-Term Sustained Intraocular Drug DeliveryR01EY033000 · NEI · PURDUE UNIVERSITY · PI LEE, CHI HWAN, PAULUS, YANNIS MANTAS · 2021 to 2025
$1.9M
E75 IN THE DEVELOPING DROSOPHILA EYEF31EY007003 · NEI · YALE UNIVERSITY · PI SHILTON, ALYCIA N · 1999 to 2001
8-arm PEG (polyethylene-glycol) is a highly promising nanoplatform due to its small size (<10 nm), ease-of-conjugation (many functionalized variants are readily available with "click-like" properties), biocompatibility, and optical inactivity. This study evaluates 8-arm PEG uptake into cells (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeted 8-arm PEG Nanosystems for Localization of Choroidal Neovascularization Macular Degeneration Model. · full record | OpenQuestion